PT Kedoya Adyaraya Tbk (RSGK.JK)
IDR 990.0
(-1.0%)
IDR 990.0
(-1.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 61.12 Billion IDR | 1.29% |
| 2022 | 76.13 Billion IDR | -45.13% |
| 2021 | 121.82 Billion IDR | 147.68% |
| 2020 | 63.12 Billion IDR | 14.97% |
| 2019 | 56.06 Billion IDR | 62.21% |
| 2018 | 43.55 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 22.96 Billion IDR | 33.07% |
| 2024 Q3 | 20.22 Billion IDR | -3.72% |
| 2024 Q2 | 19.95 Billion IDR | -8.54% |
| 2023 Q2 | 10.56 Billion IDR | -21.51% |
| 2023 Q1 | 13.46 Billion IDR | -21.76% |
| 2023 FY | - IDR | 1.29% |
| 2023 Q4 | 14.4 Billion IDR | 73.91% |
| 2023 Q3 | 8.28 Billion IDR | -21.62% |
| 2022 Q3 | 18.83 Billion IDR | 294.47% |
| 2022 Q2 | 4.77 Billion IDR | -71.17% |
| 2022 FY | - IDR | -45.13% |
| 2022 Q1 | 16.56 Billion IDR | 6143.59% |
| 2022 Q4 | 17.21 Billion IDR | -8.63% |
| 2021 Q1 | 39.7 Billion IDR | 81.25% |
| 2021 FY | - IDR | 147.68% |
| 2021 Q4 | -274.08 Million IDR | -100.92% |
| 2021 Q3 | 29.87 Billion IDR | -15.33% |
| 2021 Q2 | 35.28 Billion IDR | -11.13% |
| 2020 Q4 | 21.9 Billion IDR | 0.0% |
| 2020 FY | - IDR | 14.97% |
| 2019 FY | - IDR | 62.21% |
| 2018 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Bundamedik Tbk | 223.9 Billion IDR | 72.702% |
| PT Metro Healthcare Indonesia Tbk | -7.68 Billion IDR | 895.836% |
| PT Medikaloka Hermina Tbk | 1584.42 Billion IDR | 96.142% |
| PT Mitra Keluarga Karyasehat Tbk | 1555.38 Billion IDR | 96.07% |
| PT Murni Sadar Tbk | 155.6 Billion IDR | 60.72% |
| PT Famon Awal Bros Sedaya Tbk | 443.01 Billion IDR | 86.203% |
| PT Royal Prima Tbk | 52.4 Billion IDR | -16.627% |
| PT Sarana Meditama Metropolitan Tbk | 323.18 Billion IDR | 81.088% |
| PT Siloam International Hospitals Tbk | 2692.46 Billion IDR | 97.73% |
| PT Sejahteraraya Anugrahjaya Tbk | 437.22 Billion IDR | 86.021% |